Clinical trials: Pediatric ALL, Relapsed
Relapsed Pediatric ALL, Relapsed Pediatric AML
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
In this pilot study, eligible pediatric patients will be treated with 5 consecutive days of low dose daunorubicin. All patients who receive low dose daunorubicin will be evaluated daily for potential toxicity during those 5 days.
- Conditions
- Relapsed Pediatric ALL, Relapsed Pediatric AML, Refractory Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04562792
- Testing
- Daunorubicin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Mercy Hospital Kansas City
Recurrent Pediatric ALL, Relapsed Pediatric ALL
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
This is a phase I/II study of an investigational drug called ABT-751, produced by Abbott Laboratories, given in combination with chemotherapy drugs used to treat acute lymphoblastic leukemia (ALL) that has come back (recurred).
- Conditions
- Recurrent Pediatric ALL, Relapsed Pediatric ALL, Acute Lymphoblastic Leukemia, Refractory Pediatric ALL
- Trial name
- NCT00439296
- Testing
- ABT-751, Dexamethasone, PEG-asparaginase
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Therapeutic Advances in Childhood Leukemia Consortium